Dr. Larry Anderson, MD, PhD, from UT Southwestern Harold C. Simmons Comprehensive Cancer Center discusses their rapidly growing Myeloma Program. They are pioneering advancements in CAR T-cell therapy, stem cell transplants, and ongoing clinical trials. Their team is looking at new ways of:
Even with advances in myeloma treatment, cycles of remission and relapse continue to occur. GPRC5D has emerged as a novel therapeutic target. “Results from early phase trials of GPRC5D-targeting T-cell–redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen (BCMA) and Fc receptor-like protein 5-targeting (FcRL5) bispecific antibodies.”
“Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient’s own T-cells to kill their tumor cells and have shown impressive results in relapsed refractory myeloma.”
This therapy offers a viable and promising future for myeloma patients. Some of the latest data show:
This is an exciting era for myeloma patients. With these new CAR-T cell therapies, remissions are lasting longer. The ultimate goal is to find the right combination of treatment strategies to give patients optimal length of life.
Want to find out more about multiple myeloma? HealthTree University continuously publishes new interviews with myeloma experts covering the latest on treatment, clinical trials, and more!
Sources:
Dr. Larry Anderson, MD, PhD, from UT Southwestern Harold C. Simmons Comprehensive Cancer Center discusses their rapidly growing Myeloma Program. They are pioneering advancements in CAR T-cell therapy, stem cell transplants, and ongoing clinical trials. Their team is looking at new ways of:
Even with advances in myeloma treatment, cycles of remission and relapse continue to occur. GPRC5D has emerged as a novel therapeutic target. “Results from early phase trials of GPRC5D-targeting T-cell–redirecting agents have shown promising efficacy and manageable safety profiles, including lower infection rates compared with B-cell maturation antigen (BCMA) and Fc receptor-like protein 5-targeting (FcRL5) bispecific antibodies.”
“Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient’s own T-cells to kill their tumor cells and have shown impressive results in relapsed refractory myeloma.”
This therapy offers a viable and promising future for myeloma patients. Some of the latest data show:
This is an exciting era for myeloma patients. With these new CAR-T cell therapies, remissions are lasting longer. The ultimate goal is to find the right combination of treatment strategies to give patients optimal length of life.
Want to find out more about multiple myeloma? HealthTree University continuously publishes new interviews with myeloma experts covering the latest on treatment, clinical trials, and more!
Sources:
about the author
Lisa Foster
Lisa Foster is a mom of 3 daughters, a puzzle lover, writer and HealthTree advocate. She believes in the mission of the foundation and the team that builds it forward. She calls Houston, Texas home.
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.